Chugai Pharmaceutical clinical trials

Acquired by Hoffmann-La Roche, Oct 1, 2002 · source ↗

The registry lists 63 studies whose lead sponsor is Chugai Pharmaceutical. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 29, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 63. List all 63 → · All Hoffmann-La Roche studies →

• Study of AUBE00 in Patients With Solid TumorsRecruitingNCT07030959Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• AQUA07 in Patients With ALK-Positive Non-Small Cell Lung CancerRecruitingNCT07617337Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Study of DONQ52 in Active Celiac DiseaseRecruitingNCT07239336Phase 2

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid TumorsRecruitingNCT05907980Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)RecruitingNCT06371417Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)Enrolling by invitationNCT06723106Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCERRecruitingNCT07107490Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).CompletedNCT04511845Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid TumorsCompletedNCT05735366Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).TerminatedNCT05012618Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease PatientsCompletedNCT05425446Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Phase I Study of ERY974 in Patients With Hepatocellular CarcinomaActive, not recruitingNCT05022927Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)CompletedNCT04818983

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)CompletedNCT04501497

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)CompletedNCT05686369

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• An Observational Study of Patients With Endometriosis to Evaluate the Usefulness of the MEDL Score, a New Method for Evaluating Endometriosis Using MRICompletedNCT04846582

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy VolunteerCompletedNCT04708847Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)CompletedNCT03645330

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal OsteoporosisStatus unknownNCT05433207

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Phase 2 Study of CIM331 for Atopic Dermatitis PatientsCompletedNCT01986933Phase 2

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• PD-L1 Expression in Japanese Renal Cell Carcinoma PatientsCompletedNCT03748901

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With HypoparathyroidismTerminatedNCT04209179Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Excretion Balance, PK and Metabolism of a Single Oral Dose of [14C]PCO371CompletedNCT04649216Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRCStatus unknownNCT04097444Phase 2

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Study of ERY974 in Patient With Advanced Solid TumorsCompletedNCT02748837Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on HemodialysisCompletedNCT02965053Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30CompletedNCT02431117

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Single Ascending Dose Study of PCO371 in Healthy VolunteersTerminatedNCT02475616Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid ArthritisTerminatedNCT00779220Phase 2

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)CompletedNCT00976170Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease PatientsCompletedNCT01656525Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JPCompletedNCT00144586Phase 3

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A New Active Vitamin D, ED-71 for OsteoporosisCompletedNCT00144456Phase 3

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Study of MRA in Patients With Rheumatoid Arthritis (RA)CompletedNCT00144651Phase 2

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JPCompletedNCT00144547Phase 3

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone MetastasesCompletedNCT00060138Phase 1/2

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)CompletedNCT00746317Phase 1

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)CompletedNCT00661284

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary OsteoporosisCompletedNCT00447915Phase 3

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast CancerCompletedNCT00467012Phase 2

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Trial of Pegasys® in Patients With Chronic Hepatitis CCompletedNCT00245414Phase 4

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal CancerCompletedNCT00345761Phase 1/2

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)CompletedNCT00304551Phase 3

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)CompletedNCT00144625Phase 3

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)CompletedNCT00144612Phase 3

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)CompletedNCT00380601Phase 3

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JPCompletedNCT00144534Phase 3

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) PatientsCompletedNCT00628043Phase 3

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing ChemotherapyCompletedNCT00144482Phase 3

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche

• Clinical Study of R744 to Hemodialysis PatientsCompletedNCT00491868Phase 3

  Sponsor listed in the registry: Chugai Pharmaceutical · First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche